PhD Scientific Days 2022

Pathology and Oncology III. (Poster discussion will take place in the Aula during the Coffee Break)

Examination of Interleukin 1A and 1B single nucleotid polimorphism in development and prognosis of medication-related osteonecrosis of the jaw

Text of the abstract

Introduction: The medication-related osteonecrosis of the jaw (MRONJ) is the side effect of antiresorptive and antiangiogenic drugs in the maxillofacial region.
Aims: We examine the single nucleotid polimorphism of interleukin 1A and 1B in development and prognosis of MRONJ.
Methods: In our study we apply DentiGen Parodontitis Test for collecting samples. This test is suitable for sampling from oral mucosa cells to ascertain interleukin 1A and 1B single nucleotid polymorphism (IL-1A-889, IL-1B+3953). The genetic samples were evaluated in Istenhegyi Genediagnostic Center with DNA-hybridization technic.
In our investigation we made examination in patient group and control group. In the patient group was MRONJ diagnosted based on the 2014 recommendation of American Association of Oral and Maxillofacial Surgeons. In control group the patient didn’t suffer from MRONJ.
The role of gene polymorphism in development of the disease is examined by comparing the genetic results of patient group and control group. The investigation of gene polymorphism in prognosis of the disease is based on treatment-induced stage improvement, recovery and the relapses following the treatment.
Results: During our investigation 150 genetic examination were performed. 91 patients are suffering from MRONJ and 59 patients are in control group. In patient group 51 (56,04%) patients carry unfavourable allelic variant, in control group 22 (37,28%) patients have unfavourable allelic variant. We didn’t find any association (p=0,498) between the unfavourable polimorphism and the development of the MRONJ. In patient group were used surgical therapy in 79 cases. In this group were detected stage improvement in 78 (98,73%) cases, recovery in 67 (88,15%) cases and relapses in 33 (49,25%) cases. 49 patients have unfavourable allelic variant. We haven’t found any connection between the examined polymorphism and the stage improvement (p=0,382) or recovery (p=0,561). Significant association (p=0,022) was detected between the relapses and the carrying of unfavourable allelic variant.
Conclusion: We found significant association between relapses of MRONJ and the carrying of interleukin 1A and 1B polimorphism. Based on our study we didn’t find any association between interleukin 1 polimorphism and the development of MRONJ.
Funding: from Faculty Research Application